Venous thromboembolism continues to present a challenge to clinicians. Over
the years, a number of risk factors which predispose to venous thromboembo
liism have been identified, and these risk factors are taken into account i
n the formulation of recommendations for the prevention and treatment of th
ese disorders. In more recent years; there have, been major advances in our
understanding of congenital or acquired defects that predispose to thrombo
sis leading to these so-called acquired or inherited forms of thrombophilia
. The list of acquired forms of thrombophilia now includes anti-thrombin, p
rotein C, protein S, activated protein C resistance, the prothrombin 20210A
mutant, homocysteinemia and a number of rare defects which either enhance
coagulation or interfere with fibrinolysis. In spite of these advances, the
re are numerous families with thrombophilia in whom none of the known defec
ts can be demonstrated. The challenge for the future is to discover some of
these as yet unknown factors and to determine the most appropriate methods
for the prevention and treatment of venous thromboembolism in susceptible
individuals with thrombophilia.